Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets

Trends in Endocrinology and Metabolism

Volumn 27, Issue 5, 2016, Pages 304-318

  Tudurí, Eva ^a,b   López, Miguel ^a,b   Diéguez, Carlos ^a,b   Nadal, Angel ^c   Nogueiras, Rubén ^a,b  

^a University of Santiago de Compostela ^*  (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Diabetes; GLP 1; Glycaemic control; Insulin; cells

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; SOMATOSTATIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ANTIDIABETIC ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CELL STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DIABETES MELLITUS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS;

EID: 84962730836     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.03.004     Document Type: Review

References (100)

1. Bloomgarden Z.T. American Diabetes Association Annual Meeting, 1999: diabetes and obesity. Diabetes Care 2000, 23:118-124.
2. Schirra J., et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J. Clin. Invest. 1996, 97:92-103.
3. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
4. Vilsboll T., et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
5. Hojberg P.V., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52:199-207.
6. Elahi D., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. 1994, 51:63-74.
7. Nadkarni P., et al. Regulation of glucose homeostasis by GLP-1. Prog. Mol. Biol. Transl. Sci. 2014, 121:23-65.
8. Barnett A.H. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 2011, 6:67-79.
9. Turton M.D., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
10. Furman B.L. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon 2012, 59:464-471.
11. Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc. Bayl. Univ. Med. Cent. 2006, 19:281-284.
12. Wajcberg E., Amarah A. Liraglutide in the management of type 2 diabetes. Drug Des. Devel. Ther. 2010, 4:279-290.
13. Werner U., et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul. Pept. 2010, 164:58-64.
14. Garg S.K., Shah V.N. Newer therapies for diabetes management. Diabetes Technol. Ther. 2014, 16(Suppl. 1):S119-S127.
15. Christensen M., et al. Lixisenatide for type 2 diabetes mellitus. Expert Opin. Invest. Drugs 2011, 20:549-557.
16. Kim D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
17. Bush M.A., et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metab. 2009, 11:498-505.
18. Woodward H.N., Anderson S.L. Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Prefer. Adherence 2014, 8:789-803.
19. Jimenez-Solem E., et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 2010, 12:790-797.
20. Edwards K.L., Minze M.G. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evid. 2015, 10:11-21.
21. Blair H.A., Keating G.M. Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs 2015, 75:651-663.
22. Tornehave D., et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J. Histochem. Cytochem. 2008, 56:841-851.
23. Pyke C., et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014, 155:1280-1290.
24. Richards P., et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014, 63:1224-1233.
25. Fehmann H.C., Habener J.F. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992, 130:159-166.
26. Schmidt W.E., et al. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985, 28:704-707.
27. Drucker D.J., et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:3434-3438.
28. MacDonald P.E., et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002, 51(Suppl 3):S434-S442.
29. Stoffers D.A., et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000, 49:741-748.
30. Buteau J., et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999, 42:856-864.
31. Zhu Z.Q., et al. Calcium/calmodulin-dependent serine protein kinase is involved in exendin-4-induced insulin secretion in INS-1 cells. Metabolism 2014, 63:120-126.
32. Shao S., et al. Protective action of liraglutide in beta cells under lipotoxic stress via PI3K/Akt/FoxO1 pathway. J. Cell Biochem. 2014, 115:1166-1175.
33. Hong S.W., et al. Repression of sterol regulatory element-binding protein 1-c is involved in the protective effects of exendin-4 in pancreatic beta-cell line. Mol. Cell Endocrinol. 2012, 362:242-252.
34. Zhao X., et al. The global transcriptional response of isolated human islets of langerhans to glucagon-like peptide-1 receptor agonist liraglutide. ISRN Endocrinol. 2012, 2012:608672.
35. Toso C., et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl. Int. 2010, 23:259-265.
36. Werner U., et al. The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves β-cell function in human pancreatic islets. Ann. Meet Am. Diabetes Assoc. 2008, 68. Abstr. 11-OR.
37. Greig N.H., et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999, 42:45-50.
38. Li Y., et al. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005, 54:482-491.
39. Shimoda M., et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011, 54:1098-1108.
40. Rolin B., et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E745-E752.
41. Baggio L.L., et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
42. Thorkildsen C., et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J. Pharmacol. Exp. Ther. 2003, 307:490-496.
43. Moffett R.C., et al. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. Diabetes Metab. Res. Rev. 2015, 31:248-255.
44. Schwasinger-Schmidt T., et al. Long-term liraglutide treatment is associated with increased insulin content and secretion in beta-cells, and a loss of alpha-cells in ZDF rats. Pharmacol. Res. 2013, 76:58-66.
45. Wang L., et al. GLP-1 analog liraglutide enhances proinsulin processing in pancreatic beta-cells via a PKA-dependent pathway. Endocrinology 2014, 155:3817-3828.
46. Kimura T., et al. Protective effects of pioglitazone and/or liraglutide on pancreatic beta-cells in db/db mice: comparison of their effects between in an early and advanced stage of diabetes. Mol. Cell Endocrinol. 2015, 400:78-89.
47. Abdulreda M.H., et al. Liraglutide compromises pancreatic β cell function in a humanized mouse model. Cell Metab. 2016, 23:541-546.
48. Chang A.M., et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003, 52:1786-1791.
49. Degn K.B., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187-1194.
50. Vilsboll T., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet. Med. 2008, 25:152-156.
51. Madsbad S., et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27:1335-1342.
52. Retnakaran R., et al. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014, 37:3270-3278.
53. Trujillo J.M., Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann. Pharmacother. 2014, 48:1494-1501.
54. Thompson A.M., Trujillo J.M. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann. Pharmacother. 2015, 49:351-359.
55. Perfetti R., et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
56. Farilla L., et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143:4397-4408.
57. Buteau J., et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003, 52:124-132.
58. Buteau J., et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001, 50:2237-2243.
59. Buteau J., et al. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006, 55:1190-1196.
60. Fang D., et al. The Akt/FoxO1/p27 pathway mediates the proliferative action of liraglutide in beta cells. Mol. Med. Rep. 2012, 5:233-238.
61. Miao X.Y., et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides 2013, 39:71-79.
62. Park S., et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 2006, 281:1159-1168.
63. Rutti S., et al. In vitro proliferation of adult human beta-cells. PLoS ONE 2012, 7:e35801.
64. Tian L., et al. Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts. Transpl. Int. 2011, 24:856-864.
65. Kwon D.Y., et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J. Pharmacol. Sci. 2009, 111:361-371.
66. Tourrel C., et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001, 50:1562-1570.
67. Tourrel C., et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002, 51:1443-1452.
68. Lamont B.J., Drucker D.J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008, 57:190-198.
69. Ellenbroek J.H., et al. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia 2013, 56:1980-1986.
70. Khorsandi L., Nejad-Dehbashi F. Exendin-4 effects on islet volume and number in the mouse pancreas. Bratisl. Lek. Listy 2014, 115:502-507.
71. Sturis J., et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br. J. Pharmacol. 2003, 140:123-132.
72. Bock T., et al. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 2003, 111:1117-1124.
73. Xu G., et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
74. Farilla L. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144:5149-5158.
75. Wei Q., et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic beta-cell line. Peptides 2012, 37:18-24.
76. Chen J., et al. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem. Biophys. Res. Commun. 2006, 346:1067-1074.
77. Li Y., et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003, 278:471-478.
78. Tews D., et al. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm. Metab. Res. 2008, 40:172-180.
79. Muller W.A., et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 1970, 283:109-115.
80. Denroche H.C., et al. Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling. Diabetes 2011, 60:1414-1423.
81. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 2007, 113:546-593.
82. Yamato E., et al. Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets. Biochem. Biophys. Res. Commun. 1990, 167:431-437.
83. Fehmann H.C., et al. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 1995, 11:196-200.
84. Creutzfeldt W.O., et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996, 19:580-586.
85. Egido E.M., et al. Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas. Horm. Metab. Res. 2004, 36:595-600.
86. Silvestre R.A., et al. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur. J. Pharmacol. 2003, 469:195-200.
87. Barrington P., et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes. Metab. 2011, 13:426-433.
88. Fehse F., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2005, 90:5991-5997.
89. Stechl J., et al. Augmentation of first-phase insulin release with lixisenatide in non-diabetic subjects. Diabetologia Abstr. 2010, 814.
90. Kolterman O.G., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88:3082-3089.
91. Matsumoto S., et al. Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes. J. Clin. Biochem. Nutr. 2013, 53:68-72.
92. Froud T., et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 2008, 86:36-45.
93. Peixoto E.M., et al. Effect of exenatide on gastric emptying and graft survival in islet allograft recipients. Transplant. Proc. 2011, 43:3231-3234.
94. Drucker D.J., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
95. Degn K.B., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
96. Rosenstock J., et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32:1880-1886.
97. Barrington P., et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes. Metab. 2011, 13:434-438.
98. Buse J.B., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
99. Winzell M.S., Ahren B. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. J. Mol. Endocrinol. 2008, 40:93-100.
100. Koehler J.A., et al. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 2015, 64:1046-1056.